retatrutide dosing in trials Retatrutide—A Game Changer Obesity Pharmacotherapy Retatrutide Phase 3 Trials Breakdown

Currently, a phase 3 clinical trial program for retatrutide (TRIUMPH) is underway to assess its safety and efficacy in different obese patient populations, including those with obstructive sleep apnea (OSA), T2D, diagnosed cardiovascular disease, osteoarthritis, and others

However, missing multiple doses in a month reduces weight loss momentum and can lead to gradual regain, making consistent adherence essential for long-term success

these side effects often diminish as the body adjusts, though discontinuation rates were 2124% across doses

Treatment of HFpEF beyond the SGLT2-Is: Does the addition of GLP-1 RA improve cardiometabolic risk and outcomes in diabetic patients